Skip to main content
Jiangsu Nhwa Pharmaceutical Co.，LTD logo

Jiangsu Nhwa Pharmaceutical Co.，LTD — Investor Relations & Filings

Ticker · 002262 ISIN · CNE100000CG8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,628 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002262

About Jiangsu Nhwa Pharmaceutical Co.，LTD

https://www.nhwa-group.com

Jiangsu Nhwa Pharmaceutical Co., Ltd. is a specialized pharmaceutical enterprise focused on the research, development, manufacture, and marketing of drugs targeting the Central Nervous System (CNS). The company maintains a comprehensive product portfolio across several therapeutic areas, including anesthesiology, psychiatry, and neurology. Key product categories encompass intravenous and inhalational anesthetics, analgesics, muscle relaxants, sedatives, and antipsychotic medications. Nhwa operates integrated R&D centers and large-scale production facilities compliant with international quality standards. By prioritizing innovation in CNS therapies, the company provides clinical solutions for pain management, surgical anesthesia, and mental health disorders. Its business model integrates the entire value chain from active pharmaceutical ingredient (API) synthesis to finished dosage form production and professional medical promotion.

Recent filings

Filing Released Lang Actions
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the company’s 2025 Annual General Meeting, detailing voting results for each agenda item, shareholder attendance, vote counts, and percentages. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-15 Chinese
江苏恩华药业股份有限公司2025年度股东会法律意见书
Regulatory Filings Classification · 90% confidence The document is a legal opinion letter issued by Lifang & Partners law firm regarding the legality of the 2025 Annual General Meeting (AGM) of Jiangsu Enhua Pharmaceutical Co., Ltd. It is a lawyer’s attestation on the AGM process, attendance qualifications, voting procedures, and results. This is a certification/attestation rather than the AGM materials themselves or a standalone vote‐result announcement. According to the “certification rule,” officer or professional attestation letters should be classified as Regulatory Filings (RNS), which serves as the fallback for compliance documents and certifications.
2026-05-15 Chinese
关于续聘会计师事务所的公告
Regulatory Filings Classification · 78% confidence The document is an announcement by Jiangsu Enhua Pharmaceutical Co. regarding the board’s resolution to renew (reappoint) its external auditor (Lixin CPA Firm) for the 2026 audit. It does not contain the audit report itself, nor detailed financial results, nor is it a proxy statement or report publication notice. It is a regulatory announcement about corporate compliance steps, which does not fit any more specific category. Therefore, it should be classified under the general Regulatory Filings (RNS) category.
2026-04-17 Chinese
关于关联方资金占用及对外担保情况的专项报告
Audit Report / Information Classification · 85% confidence The document is a standalone special report on related-party non-operating fund occupancy and external guarantees, audited by an accounting firm with an unqualified opinion. It is not a full annual or interim report, not a meeting notice or call transcript, but a specific audit-related disclosure. This aligns with the “Audit Report / Information” category (AR).
2026-04-17 Chinese
关于举办2025年度业绩说明会的公告
Investor Presentation Classification · 80% confidence The document is an announcement by Jiangsu Enhua Pharmaceutical Co., Ltd. regarding the scheduling and format of its 2025 annual performance explanation meeting (webcast for investors), listing presenters and participation details. This is not the release of financial results (ER), a management discussion (MDA), or a transcript (CT), but rather the announcement of an investor-focused presentation event. It therefore best fits the Investor Presentation category (IP).
2026-04-17 Chinese
关于公司董事、高级管理人员2025年度薪酬确定及 2026年度薪酬方案的公告
Remuneration Information Classification · 91% confidence The document is a public announcement by Jiangsu Enhua Pharmaceutical Co., Ltd. detailing the 2025 annual compensation paid to directors and senior management and the proposed 2026 compensation scheme. It includes a table of individual remuneration amounts for board members and senior executives, as well as descriptions of the compensation policy. This matches the definition of Remuneration Information (Code: DEF 14A), which covers reports detailing compensation for top executives and directors.
2026-04-17 Chinese

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.